CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 27, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today the election of Judy Lieberman, M.D., Ph.D., to its Scientific Advisory Board. Dr. Lieberman is Senior Investigator at the CBR Institute for Biomedical Research and Professor of Pediatrics, at Harvard Medical School, and the Director of the Division of AIDS at Harvard Medical School. She is a graduate of Radcliffe College, Harvard University. After receiving her Ph.D. in physics from Rockefeller University, she worked in high-energy physics at the Institute for Advanced Study in Princeton and the Fermi National Accelerator Laboratory. Later, Dr. Lieberman earned an M.D. in the joint Harvard-MIT Program in Health, Science, and Technology, and completed her internal medicine residency and hematology-oncology subspecialty training at Tufts-New England Medical Center in Boston, and her postdoctoral work at Massachusetts Institute of Technology.
